AVADEL PHARMACEUTICALS PLC 8K

Alkermes plc closed its all‑cash, debt‑financed acquisition of Avadel Pharmaceuticals plc and its narcolepsy drug LUMRYZ on February 12, 2026, expanding into sleep medicine and projecting the deal to be earnings accretive in 2026.

On February 12, 2026, Alkermes plc completed its court‑sanctioned acquisition of Avadel Pharmaceuticals plc via an Irish scheme of arrangement, adding Avadel’s FDA‑approved narcolepsy drug LUMRYZ and its related pipeline asset valiloxybate to Alkermes’ commercial and R&D portfolio, financed through approximately $750 million of balance sheet cash and $1.525 billion of new term loans due 2031. The transaction accelerates Alkermes’ entry into the sleep medicine market, expands its commercial infrastructure in central disorders of hypersomnolence, and is expected to be accretive in 2026. Alkermes disclosed expected 2026 financial effects including $40 million of transaction costs in Q1 2026, approximately $180 million of LUMRYZ inventory fair value step‑up to be expensed as cost of goods sold, recognition of about $1.5 billion of LUMRYZ‑related intellectual property amortized over 13 years with 2026 amortization of $95–$105 million, and net interest expense of $75–$85 million. Following Irish High Court approval of the scheme on February 10, 2026 and Avadel shareholder approvals on January 12, 2026, Avadel’s shares will cease trading and be delisted from Nasdaq, with Alkermes commencing payment of the cash consideration and issuance and registration of contingent value rights for eligible Avadel shareholders on the February 12, 2026 effective date.

Filing Facts

CIK

1012477

Ticker

AVDL

Form

8K

Source Type

fda

Accession

0001104659-26-013880

Alert Tier

8